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AbsTrACT
Introduction chronic non- invasive ventilation (niV) 
has become evidence- based care for stable hypercapnic 
cOPD patients. While the number of patients increases, 
home initiation of niV would greatly alleviate the 
healthcare burden. We hypothesise that home initiation 
of niV with the use of telemedicine in stable hypercapnic 
cOPD is non- inferior to in- hospital niV initiation.
Methods sixty- seven stable hypercapnic cOPD patients 
were randomised to initiation of niV in the hospital or at 
home using telemedicine. Primary outcome was daytime 
arterial carbon dioxide pressure (PacO2) reduction after 
6 months niV, with a non- inferiority margin of 0.4 kPa. 
secondary outcomes were health- related quality of life 
(hrQol) and costs.
results home niV initiation was non- inferior to in- 
hospital initiation (adjusted mean difference in PacO2 
change home vs in- hospital: 0.04 kPa (95% ci −0.31 to 
0.38 kPa), with both groups showing a PacO2 reduction 
at 6 months compared with baseline (home: from 
7.3±0.9 to 6.4±0.8 kPa (p<0.001) and in- hospital: from 
7.4±1.0 to 6.4±0.6 kPa (p<0.001)). in both groups, 
hrQol improved without a difference in change between 
groups (clinical cOPD Questionnaire total score- adjusted 
mean difference 0.0 (95% ci −0.4 to 0.5)). Furthermore, 
home niV initiation was significantly cheaper (home: 
median €3768 (iQr €3546–€4163) vs in- hospital: 
median €8537 (iQr €7540–€9175); p<0.001).
Discussion This is the first study showing that home 
initiation of chronic niV in stable hypercapnic cOPD 
patients, with the use of telemedicine, is non- inferior 
to in- hospital initiation, safe and reduces costs by over 
50%.
Trial registration number ncT02652559.
INTroDuCTIoN
Long- term non- invasive ventilation (NIV) has long 
been controversial in patients with stable Chronic 
Obstructive Pulmonary Disease (COPD) and 
chronic hypercapnic respiratory failure (CHRF).1–7 
However, with the introduction of high- intensity 
NIV, defined as a mode of ventilation with higher 
inspiratory pressures and a higher backup respi-
ratory rate (BURR) aimed at a more controlled 
form of ventilation and improvement in gas 
exchange,8 9 clinically relevant improvements have 
also been shown in COPD, without undue loss of 
patient comfort.10–17 On the basis of these positive 
results, chronic NIV set up to target substantial 
arterial carbon dioxide reduction has become the 
standard of care for patients with severe stable 
COPD and CHRF.
Initiation of high- intensity NIV is a delicate 
process of achieving sufficient ventilatory support 
while keeping patients comfortable and avoiding 
side effects. Historically, it has been believed that 
initiation and titration of chronic NIV targeted 
at a substantial arterial carbon dioxide reduction 
requires a hospital admission.10 16 Since the number 
of patients with COPD, who will be initiated on 
chronic NIV, in the Netherlands is expected to 
rise in the coming years, so will the burden on our 
healthcare system. For instance, at our centre, the 
number of COPD patients initiated on chronic NIV 
increased from 10 in 2015 (7% of the total number 
of patients initiated on chronic NIV) to 76 in 2017 
(33% of the total number of patients initiated on 
chronic NIV).
Home initiation of NIV would greatly alleviate 
the burden on the healthcare system and would 
prevent demanding hospital visits in a disabled 
dyspnoeic patient population, but needs to be 
proven safe, effective and cost- effective. In patients 
with neuromuscular disease, it has been shown that 
initiation of chronic NIV at home, with the use of 
Key messages
What is the key question?
 ► Is home initiation of non- invasive ventilation 
(NIV) in stable hypercapnic COPD non- inferior 
to in- hospital NIV initiation?
What is the bottom line?
 ► Home initiation of chronic NIV in stable 
hypercapnic COPD patients is non- inferior to 
in- hospital initiation, safe and saves over 50% 
of the costs.
Why read on?
 ► This is the first randomised controlled trial 
showing that home initiation of chronic NIV 
in COPD patients with chronic hypercapnic 
respiratory failure is non- inferior to hospital 
initiation, and is associated with savings of over 
50% of the costs.
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Figure 1 Figure 1Consort diagram of the RECONSIDER trial. One patient that was non- compliant and stopped his NIV was followed for outcome 
measurements (shown in italic). FEV1, Forced Expiratory Volume in 1 second; NIV, non- invasive ventilation.
telemonitoring, is non- inferior to initiation in the hospital.18 
However, neuromuscular patients are initiated on NIV with 
lower ventilator settings, and therefore might adapt more easily 
to their NIV. We hypothesised that with extensive possibilities 
for remote monitoring of ventilator parameters and transcuta-
neous carbon dioxide (PtCO2) using telemedicine, home initi-
ation of chronic NIV targeted at a substantial arterial carbon 
dioxide reduction in stable hypercapnic COPD is non- inferior to 
in- hospital NIV initiation.
MeThoDs
Design
In a monocentre, 1:1 randomised controlled parallel- group trial, 
we tested the hypothesis that home initiation of chronic NIV 
targeted at a substantial arterial carbon dioxide reduction is non- 
inferior to in- hospital initiation in COPD patients with CHRF, 
in terms of daytime arterial carbon dioxide pressure (PaCO2) 
reduction after 6 months. Data monitoring and validation was 
performed by an independent certified data monitor from the 
Research Data Support of the University Medical Center Gron-
ingen, and a data safety monitoring board was instituted that 
monitored all adverse events throughout the study.
Patients
From June 2016 to December 2017, all patients with stable 
COPD and CHRF referred to or home mechanical ventilation 
(HMV) centre unit with an indication for chronic NIV were 
informed about the study. Inclusion criteria were: (1) COPD 
GOLD (Global Initiative for Chronic Obstructive Lung Disease19 
stage III or IV (post- bronchodilator Forced Expiratory Volume 
in 1 second (FEV1)/Forced Vital Capacity (FVC)<70% and 
FEV1<50% of predicted); (2) daytime PaCO2 at room air>6.0 
kilopascal (kPa) in stable condition, defined as no COPD exac-
erbation during the last 4 weeks, and a pH>7.35; (3) age>18 
years; (4) existence of a sufficient social support network making 
initiation of HMV at home possible and (5) written informed 
consent. Exclusion criteria were: (1) unstable severe cardiac 
comorbidities (left ventricular ejection fraction below 45% and 
unstable angina pectoris complaints); (2) living in a nursing 
home and (3) previous or current use of Continuous Positive 
Airway Pressure (CPAP or NIV in the home setting (prior NIV 
during exacerbations was allowed).
outcome parameters
The primary study outcome was the change in PaCO2 measured 
during spontaneous breathing at room air at daytime after 6 
months compared with baseline. PaCO2 was assessed with arte-
rial blood gas analysis by puncture of the radial artery at least 3 
hours after cessation of the nocturnal NIV.
Secondary outcomes were safety, symptoms and health- related 
quality of life (HRQoL), measured by the Severe Respiratory 
Insufficiency Questionnaire (SRI),20 the Medical Outcomes 
Study 36- Item Short- Form Health Survey,21 the Clinical COPD 
Questionnaire (CCQ),22 the Hospital Anxiety and Depres-
sion Scale,23 and the Medical Research Council score to assess 
dyspnoea24; lung function25 26; exercise tolerance, assessed by 
the 6 min walking distance27; compliance with the ventilator, 
exacerbation and hospitalisation frequency (assessed by checking 
medical records from the hospital and the general practitioner 
and by checking pharmacy read- outs for courses or predniso-
lone and/or antibiotics prescribed for COPD exacerbations) and 
costs. The direct (medical and non- medical) and indirect costs 
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Table 1 Baseline characteristics of the randomised patients
home, N=33 hospital, N=34 P value
Age, years 63.6±8.6 63.1±7.0 0.80
Male sex, n (%) 15 (45%) 12 (35%) 0.46
Active smokers, n (%) 4 (12%) 9 (27%) 0.22
Packyears 37.4±18.7 47.6±25.8 0.07
LTOT n (%) 26 (79%) 28 (82%) 0.77
BMI, kg/m2 24.9±6.0 25.7±4.1 0.52
Inhaled long- acting beta- 
agonists, n (%)
32 (97%) 31 (91%) 0.61
Inhaled long- acting anti- 
cholinergics, n (%)
29 (88%) 31 (91%) 0.71
Inhaled corticosteroids, n (%) 27 (82%) 28 (82%) 0.99
Morphine, n (%) 11 (33%) 8 (24%) 0.43
Oral corticosteroids, n (%) 15 (46%) 12 (35%) 0.46
Previous NIV experience during 
AECOPD, n (%)
16 (48%) 17 (50%) 0.90
  Episodes of NIV for AECOPD, 
median (range)
1 (1–3) 1 (1–2) 0.33
  Time span NIV for 
AECOPD—inclusion, days, 
median (range)
106 (34–2555) 172 (30–1825) 0.19
Exacerbations, previous 12 
months, median (IQR)
4 (1–8) 3 (1–5) 0.31
Hospitalisations, previous 12 
months, median (IQR)
1 (0–2) 1 (1–2) 0.86
Rehabilitation, n (%) 7 (21%) 8 (24%) 0.99
ESS score, points 5.8±3.9 7.1±4.6 0.26
AHI (events/hour), median 
(IQR)
2.9 (0.5–5.6) 1.4 (0.8–2.9) 0.38
Number of patients with 
AHI>15, n (%)
1 (3%) 2 (6%) 0.99
Data are shown in mean and SD unless otherwise stated.
AECOPD, acute exacerbation of COPD; AHI, apnoea/hypopnea index; BMI, body 
mass index; ESS, Epworth Sleepiness Scale;IQR, interquartile range 
; LTOT, long- term oxygen therapy; NIV, non- invasive ventilation.
of NIV initiation at home were compared with in- hospital NIV 
initiation over a 6- month period using a societal perspective.28 




All patients visited our outpatient clinic for a baseline assessment 
of demographics, exercise tolerance, lung function and measure-
ment of daytime gas exchange. All patients underwent an echo-
cardiogram and a polygraphy (at home) prior to NIV initiation 
to characterise the population (for details see online repository). 
One of the investigators enrolled patients into the study once 
they fulfilled all criteria.
Hospital NIV initiation
Patients randomised to in- hospital initiation were initiated on 
chronic NIV according to the regular procedures on our pulmo-
nary ward. We used a bilevel positive airway pressure (BiPA-
P)- set ventilator (BiPAP A40 and BiPAP A30, Philips Respironics, 
Murrysville, Pennsylvania, USA) and adjusted the settings to 
achieve normocapnia during the night or at least a reduction in 
nocturnal mean PtCO2of 20% compared with the first night of 
spontaneous breathing.29 The initiation period was finished and 
the patient was discharged home once he or she could sleep at least 
6 consecutive hours with the ventilator and the gas exchange goals 
were achieved. When necessary, our specialised nurse joined the 
patients at home to instal the ventilator.
Home NIV initiation
Patients randomised to home initiation were initiated on chronic 
NIV completely at their home, using telemedicine. Ventilator 
data were retrieved via a GPRS system clicked on the back of 
the ventilator (BiPAP A40 and BiPAP A30, Philips Respironics), 
which sent data to an online platform (Encore Anywhere, Philips 
Respironics). Changes in ventilator settings could be made 
remotely. Also, PtCO2 was measured (SenTec DM, Software 
V- STATS V.4.0, SenTec AG, Therwil, Switzerland) and these 
data were retrieved remotely via a high- end ambulatory remote 
monitoring device (Dyna- vision, Techmedic International, Broek 
op Langedijk, the Netherlands). The specialised nurse visited the 
patient at day 1 to instal the equipment, explain all procedures, 
and to practice with NIV, and the last day to return the tele-
medicine/measurement devices and finish the initiation period. 
For a detailed explanation of the home initiation, see online 
repository.
Follow-up
All patients visited the outpatient clinic 3 months (limited assess-
ment) and 6 months (full assessment) after the NIV was initi-
ated and follow- up measurements were performed by one of the 
investigators, who were not blinded to the allocation sequence. 
Patients could contact us by telephone whenever they had any 
questions.
statistics
We defined a non- inferiority margin of 0.4 kPa for the difference 
in change of our primary endpoint, PaCO2, between home and 
in- hospital initiation, as a difference in the reduction of less than 
0.4 kPa was deemed to be clinically irrelevant to base treatment 
preference. This decision was made based on previous trials, 
showing clinically relevant benefits with PaCO2 changes of more 
than 0.45 kPa.8 12 14 16 17 30 31 With a one- sided alpha of 0.025, a 
beta of 0.2, a Standard Deviation (SD) of 0.412 16 and expected 
drop out rate of 25%,17 62 patients needed to be randomised. 
Randomisation was performed automatically (ALEA randomis-
ation management, FormsVision BV, Abcoude, the Netherlands) 
with minimisation for baseline PaCO2 (≥7 or <7 kPa) and 
planned pulmonary rehabilitation (yes/no).
The primary analysis was performed including all patients that 
had at least a measurement at baseline and after 6 months, irrespec-
tive of NIV compliance. Additionally, a per- protocol analysis was 
performed, including all patients who were compliant with their 
NIV and who completed the study. Safety analyses were performed 
on all randomised patients who received NIV.
Differences in baseline variables between the home and in- hos-
pital groups, and between the completers and the drop outs were 
tested with a t- test or Mann- Whitney U test for continuous vari-
ables and χ2 tests for categorical variables. To test changes within 
a group over time, a general linear repeated measures analysis 
of variance with Bonferroni correction or a paired t- test was 
performed.
To test the null hypothesis that home initiation is non- inferior 
to in- hospital initiation, we calculated the absolute change 
in PaCO2 from baseline to 6 months and performed a linear 
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Table 2 Gas exchange
home, N=23 hospital, N=26
Adjusted mean difference in change home versus
in- hospital (95% CI)
baseline 3 months 6 months baseline 3 months 6 months 6 months–baseline
PaCO2, kPa 7.3±0.9 6.7±0.9* 6.4±0.8** 7.4±1.0 6.5±0.5* 6.4±0.6** 0.04 (−0.31 to 0.38)
PaO2, kPa 6.8±1.3 7.5±1.5 7.6±1.2 7.3±1.5 8.1±1.4* 8.0±1.2 −0.18 (−0.85 to 0.49)
HCO3
-, mmol/L 33.1±3.8 30.8±3.2* 29.8±2.9* 33.6±4.2 30.2±2.1* 29.7±2.8** 0.2 (−1.5 to 1.2)
Data are shown as mean±SD. A positive mean difference means an increase from baseline to 6 months for the home compared with the in- hospital group.
Compared with baseline within the group: *p<0.05 and **p<0.001.
HCO3-, bicarbonate; kPa, kilopascal; PaCO2, partial arterial carbon dioxide pressure; PaO2, partial arterial oxygen pressure.
Figure 2 Arterial carbon dioxide pressure (PaCO2) at daytime during spontaneous breathing without NIV. Shown are individual patient values of the 
home and hospital groups and the mean value (home: ∆; hospital: □). 3 mo, 3 months after NIV initiation; 6 mo, 6 months after NIV initiation; NIV, 
non- invasive ventilation.
regression analysis with correction for the baseline value calcu-
lating the adjusted mean difference between the groups. Other 
outcomes were tested in the same way. For outcome variables 
for which the change had a skewed distribution, the difference 
in change was tested with a Mann- Whitney U test. SPSS V.25.0 
was used to perform the analyses.
resulTs
baseline characteristics
The study flow chart is shown in figure 1. A total of 117 
patients were screened as outpatients and 67 were randomised 
when they met all inclusion criteria, and subsequently planned 
for NIV initiation as soon as possible. Three patients dropped 
out during this period before they were initiated on NIV; one 
patient died, one patient exacerbated and was initiated on NIV 
acutely and one patient refused to participate further. The 
‘waiting period’ was >30 days in 10 out of 31 patients (32%) 
with a median of 22 days (range 5–62 days) in the in- hospital 
group, while it was >30 days in 5 out of 30 patients (17%) 
with a median of 21 days (range 7–53) days in the home group 
(difference not significant). Five patients in the home group, 
and four patients in the hospital group, were non- compliant 
with their NIV. Hospital initiation was offered in the non- 
compliant home group patients, but none of them wanted 
an in- hospital attempt. In total, three patients died during 
NIV therapy. Table 1 presents the baseline characteristics. 
Comorbidities were prevalent (online supplementary table 
1). Patients with unstable cardiac comorbidities or severe 
heart failure (left ventricular ejection fraction below 45%) 
were excluded. In the included patients, cardiac function was 
generally well- preserved and comparable between the home 
and hospital groups in terms of systolic and diastolic left/right 
ventricular functional parameters (online supplementary table 
1). According to echocardiography guidelines, eight patients 
in the home group (25%) and seven patients in the hospital 
group (21%) were considered to have a high probability of 
pulmonary hypertension (p=0.49; online supplementary table 
1).32 There were no significant differences between the home 
and hospital groups (table 1), nor between participants that 
dropped out and participants that did not drop out, except 
that the latter group less frequently followed a concurrent 
pulmonary rehabilitation programme (online supplementary 
table 2).
Gas exchange
In both groups, daytime PaCO2 decreased significantly over the 6 
months follow- up period (table 2, figure 2). The mean difference 
in change between the home group versus the hospital group at 
6 months was 0.04 kPa (95% CI −0.31 to 0. 38 kPa), showing 
non- inferiority of home NIV initiation. Other parameters of 
gas exchange improved in both groups, also without significant 
differences between groups.
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Table 3 Lung function and exercise tolerance
home, N=21 hospital, N=28
Adjusted mean difference in change 
home versus in- hospital
(95% CI)
baseline 6 months baseline 6 months 6 months–baseline
FEV1, L 0.60±0.16 0.63±0.20 0.60±0.20 0.68±0.30* −0.05 (−0.14 to 0.03)
FVC, L 2.19±0.55 2.23±0.85 1.94±0.49 2.23±0.90* −0.31 (−0.67 to 0.05)
TLC, L† 7.4±1.6 7.8±1.5 7.1±1.3 7.3±1.2 0.2 (−0.4 to 0.7)
RV, L 4.9±1.3 5.2±1.2 5.0±1.2 4.9±0.9 0.4 (−0.2 to 0.9)
RV%TLC 65±7 67±10 69±7 67±9* 4 (−0.4 to 8)
6MWD, m 179±93 212±100* 194±85 231±90* −7 (−49 to 34)
Data are shown as mean±SD. A positive mean difference means an increase from baseline to 6 months for the home compared with the in- hospital group.
*P<0.05.
†Body plethysmography was performed in 16 (home) and 25 (in- hospital) patients, and the 6MWD in 22 (home) and 26 (in- hospital) patients.
FEV1, Forced Expiratory Volume in 1 second 
; FVC, Forced Vital Capacity 
; 6MWD, 6 min walking distance; RV, residual volume; TLC, total lung capacity.
Figure 3 Change in HRQoL per group. Data are shown as mean±SD. For the CCQ, a decrease means an improvement in HRQoL (Minimal Clinical 
Important Difference −0.4 points). For the SRI, an increase means an improvement in HRQoL. HRQoL: health- related quality of life; CCQ: Clinical COPD 
Questionnaire; SRI: Severe Respiratory Insufficiency questionnaire, with its domains: RC: respiratory complaints; PF: physical functioning,AS: attendant 
symptoms and sleep; SR: social relationships; AX: anxiety; WB:psychological well- being; SF: social functioning, SS: summary score.
lung function
There were no significant differences in improvement in FEV1, 
FVC and lung volumes between the arms (table 3). Both groups 
improved their 6 min walking distance, but there was no differ-
ence between the groups.
health-related quality of life
In both groups, the CCQ improved after 6 months (home 
group: 3.4±0.8 to 2.9±1.0 points (p<0.05) and hospital group: 
3.3±1.0 to 2.8±1.1 points (p<0.05)), without difference 
between the groups (figure 3). The SRI showed improvements, 
especially in physical functioning, respiratory complaints and 
attendant symptoms in both groups (figure 3). The SRI well- 
being and summary score improved significantly only in the 
hospital group. Anxiety and depression symptoms and dyspnoea 
did not change. Nevertheless, for all parameters mentioned, 
there were no differences in change between the hospital and 
at- home groups, showing non- inferiority of home initiation with 
respect to HRQoL and symptoms (online supplementary table 
3).
exacerbations and hospitalisations for CoPD exacerbations
There was no difference in change in number of hospital days, 
hospitalisation frequency and exacerbation frequency comparing 
the 6 months prior to inclusion to the study period between the 
two groups (online supplementary table 4).
Ventilatory settings, interface, duration of NIV adaptation and 
compliance
At home, NIV initiation took considerably longer time (14.5 
days, range 7–40 days) than in the hospital group (7 days, range 
4–15 days; p<0.001). All patients were initiated on a full- face 
mask, except for three patients in the home group and one 
patient in the hospital group who were initiated on a nasal mask. 
Of those patients, only one patient remained on a nasal mask, 
while the other patients switched during the 6 months follow- up 
to a full- face mask because of excessive leakage.
In general, patients in the hospital group were ventilated with 
a higher inspiratory positive airway pressure (IPAP), expiratory 
positive airway pressure (EPAP) and BURR. In the home group, 
the IPAP was increased gradually over the follow- up period, 
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Table 4 Ventilatory settings
Group
home, N=25 hospital, N=28
baseline 3 months 6 months baseline 3 months 6 months
IPAP, cm H2O 21.0±2.8 22.1±2.9* 23.6±2.3* 24.3±3.6† 24.7±3.3† 25.7±3.4*†
EPAP, cm H2O 4.5±0.8 4.6±0.9 4.6±0.9 5.7±1.2† 5.8±1.2† 6.0±1.3†
IPAP–EPAP, cm H2O 16.5±2.6 17.5±2.5* 19.0±2.1* 18.6±3.3† 18.9±2.8† 19.7±2.7*
BURR, breaths/min 13.5±2.5 13.8±2.2 13.9±2.0 15.6±2.9† 15.3±2.9† 15.4±3.0†
*Significant increase from baseline to 3 months or from 3 months to 6 months.
†Significant difference between the groups at equal time points.
BURR, backup respiratory rate; EPAP, expiratory positive airway pressure;IPAP, inspiratory positive airway pressure.
Figure 4 Costs (€) of NIV initiation hospital versus at home. Represented as median costs (€). Material: costs of the ventilator, telemedicine material 
and material/device for transcutaneous measurements; travel km: costs for travel kilometres of the specialised respiratory nurse; travel time: costs for 
travel time to the patients of the specialised respiratory nurse; telephone contact: costs for the time spend by the respiratory nurse to have telephone 
contact with the patients; nurse time: costs of the time spend by the specialised nurse directly with the patient; ward days: costs of the ward days. 
*p< 0.001. NIV, non- invasive ventilation.
while in the hospital group, this was not evident (only a small 
but significant increase between 3 and 6 months). Therefore, the 
IPAP–EPAP difference was significantly higher in the hospital 
group at 3 months, but not at 6 months (table 4).
Compliance with NIV was good. At 3 months, compliance 
was higher in the home group compared with the hospital 
group. Patients in the home group used their NIV a mean of 
7.7±1.7 hours per day (median: 95% of the total number of days 
(range 43%–100%)) compared with 6.6±2.1 hours use per day 
(median: 94% of the total number of days (range 50%–100%)) 
in the hospital group (p=0.037). Patients initiated in the hospital 
increased their compliance over time to 7.5±2.0 hours per day 
(p=0.028) (median percentage of the total number of days 97% 
(range 81%–100%)) at 6 months, while this remained good in 
the home group (8.2±1.7 hours per day (median: 99% of the 
total number of days (range 84%–100%))), so that no significant 
difference in compliance could be observed at this time point.
Time investment and costs
Initiating NIV at home costs less than half (€3768) compared 
with hospital initiation (€8537), mainly driven by the costs of 
admission to the respiratory ward (figure 4, table 5). The total 
time spent directly with the patient was not different between 
the groups. In the home group, the telephone contact time was 
longer, as was the number of kilometres driven and the travel 
time of the nurse to travel to patients’ homes. Differences 
occurred only during the initiation period, as costs during the 
follow- up were not different between groups.
safety analysis and technical problems
In the hospital group, one patient (3%) died at home unexpect-
edly after 199 days of successful NIV. In the home group, two 
patients (6%) died; one patient died 3 days after formal NIV 
initiation suddenly at home because of respiratory failure (she 
used her NIV only once at daytime for 10 min and only at day 
1) and one patient decided for euthanasia after 20 days NIV at 
home, while having improved gas exchange but without subjec-
tive benefit.
At home, technical problems with nocturnal measurements 
and transfer of transcutaneous gas exchange data occurred 
frequently, necessitating additional home visits or daytime 
measurements. Nocturnal hypoventilation was corrected equally 
between the groups (online supplementary table 5).
Side effects of NIV occurred in seven (28%) and five (18%) of 
the patients in the home and hospital groups (non- significant), 
respectively, and consisted of aerophagia (two vs two patients), 
mask decubitus (three vs three patients), excessive dyspnoea 
when NIV was disconnected in the morning (so- called ‘deven-
tilation’ dyspnoea (one patient)) and a dry mouth (one patient). 
Side effects were a reason to discontinue NIV (intermittently) 
in two patients, while in the other patients, the problems were 
either accepted or solved by changing the settings or the mask.
Per-protocol analysis of the primary outcome
Per- protocol analysis, excluding all non- compliant patients, 
showed similar results (online supplementary table 6).
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Table 5 Total costs (€) per patient from NIV initiation to 6 months follow- up
Group home, N=25 hospital, N=28
Devices Units Cost, € Units Cost, €
BiPAP A30 1 2500 1 2500
GPRS unit/Telemonitoring* – 19.2 – –
Dyna- vision† – 78 – –
Initiation period Units Cost, € Units Cost, €
Ward days for NIV initiation, n – – 7.5 (4–15) 4815 (2568–9630)¶
Nocturnal PtCO2 measurement‡, n/patient 3 (2.5–4) 108 (90–144) 3 (3–4) 108 (108–144)
Ventilatory specialist time directly with the patient, min 250 (205–323) 187 (153–241) 275 (230–314) 206 (172–235)
Telephone contact time (including calls directly after discharge), min 85 (68–108) 64 (50–80) 0 (0–10)¶ 0 (0–7)¶
Travel time by nurse, min 405 (262–482) 303 (196–361) 0 (0–200)¶ 0 (0–150)¶
Travel km by nurse 620 (278–722) 118 (53–137) 0 (0–60)¶ 0 (0–11)¶
Travel km by patient – – 215 (24–327)¶ 41 (5–62)¶
Follow- up period Units Cost, € Units Cost, €
Nocturnal PtCO2 measurement‡, n/patient 2 (2–3) 72 (72–108) 2 (2–2.75) 72 (72–99)
Ventilatory specialist time directly with the patient, min 80 (35–168) 60 (26–125) 105 (45–146) 79 (34–109)
Telephone contact time, min 30 (10–65) 22 (0–135) 20 (0–44) 15 (0–82)
Travel time by nurse, min 160 (85–364) 120 (64–272) 195 (54–355) 146 (40–266)
Travel km by nurse 237 (36–600) 45 (7–114) 219 (36–496) 42 (7–94)
Travel km by patient 320 (237–675) 61 (45–128) 270 (139–552) 51 (26–105)
Work productivity§ – – – –
Total medical costs   3709 (3480–4029)   8406 (7490–9003)
Total costs (medical and non- medical)   3768 (3546–4163)   8537 (7540–9175)
Data are presented as median (IQR) as the distribution of the data was skewed.
*The selling price of the GPRS unit was €480, depreciation of €48 per year; we used 5 units for 25 patients to be initiated in 2 years=€480, that is, in total=€19.20/patient. 
Running of the GPRS unit was included in this price.
†The Dyna- vision selling price is ~€1000, depreciation of €100 per year; we used 2 devices for 2 years to initiate 25 patients=€400=€16 euro per patient. The Dyna- vision 
requires a service for the online platform which costs €62/months=€62*25 months=€1550 in total=€62/patient.
‡The transcutaneous monitor selling price is ~€10 868, depreciation of €2604 per year. As these devices are used very frequently in regular care, we estimated that depreciation 
per night use was €11 (estimated use: 240 nights per year). Additionally, costs for material (sensor/membrane, etc) were estimated at €25, resulting in €36 per measurement.
§Only one patient still had a paid job and therefore, these costs were not taken into account.
¶ P <0.05
BiPAP, bilevel positive airway pressure; NIV, non- invasive ventilation; PtCO2, transcutaneous carbon dioxide.
DIsCussIoN
This is the first study showing that home initiation of chronic 
NIV in stable hypercapnic COPD patients, with the use of 
telemedicine, is non- inferior to in- hospital initiation, safe and 
reduces costs by over 50%.
In most countries, NIV is initiated in the hospital,33 especially 
in COPD patients who require high- intensity NIV. It is gener-
ally thought that NIV initiation should be hospital- based, but 
there is little consensus on how and where it should exactly be 
organised: the settings in which it is done (ie, pulmonary ward, 
respiratory care unit and intensive care unit) vary considerably, 
as do the costs. We hypothesised that NIV initiation in COPD 
requires careful titration and monitoring, but not necessarily 
in the hospital. A recent trial showed that nurse- led overnight 
NIV titration using transcutaneous oxi- capnometry was even 
more effective than extensive polysomnographic monitoring 
and retrospective NIV modification,34 as is sometimes thought 
to be necessary. We also monitored only gas exchange and venti-
lator data, although retrospectively on a daily basis, as we did 
not experience the time- pressure of early hospital discharge. 
We showed that this way of telemedicine- based monitoring is 
feasible at home. At home, patients are allowed to take more 
time, resulting in a more relaxed way of getting used to the high 
pressures necessary to reach the targets, that is, improvement in 
gas exchange, respiratory muscle unloading, comfort and patient 
compliance.
NIV initiation at home has been investigated before,18 35–37 
but not in COPD. Previously, we showed that initiation of NIV 
can safely be performed at home in patients with neuromuscular 
and restrictive thoracic diseases. Initiation of NIV at home was 
preferred by the patients, was equally effective and saved costs 
compared with inpatient initiation.18 In line with these findings, 
all patients recruited in the present study were, of course, willing 
to accept the possibility of home initiation; in fact, in 64 of 67 
included patients, this was the option they hoped for.
We observed that ventilatory pressures and BURR were 
higher in the hospital group. Overall, this might be an expla-
nation for the tendency to more improvement in lung function 
in the hospital group compared with the home group. Of note, 
in one- third of the transcutaneous gas exchange measurements, 
a technical problem hindered either reliable measurement of 
PtCO2 at home or the transfer of the data to the hospital. This 
resulted in extra home visits (and extra costs) and, although 
much effort was done to prevent this, probably less strict CO2- 
directed NIV titration initially. Although this surely needs to 
be improved, after 6 months, there was no difference between 
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home and hospital initiation in change in our primary outcome, 
that is, daytime PaCO2, nor in HRQoL or exercise tolerance. We 
hypothesise that the slightly lower pressures might have been 
counterbalanced by the slightly better compliance in the home 
group. Overall, differences in clinical outcomes from a clinical 
point of view were small, and, in our opinion, were more than 
balanced by the financially and patient- preferred approach of 
at- home NIV initiation.
Drop out rates tended to be higher in the home group 
compared with the hospital group. However, drop out rates 
(22% in the home group and 16% in the hospital group) from 
the included severe COPD population were comparable to 
drop out rates in regular care in our centre (overall~15%–25% 
within 6 months). Of note, but not surprisingly, adding a struc-
tured pulmonary rehabilitation programme after NIV initiation, 
as promoted in our centre, seemed to be of benefit to increase 
compliance. There was no difference in deaths, two versus one 
patient; the total number being in line with the severity of their 
baseline chronic respiratory failure and severely reduced lung 
function.12 Exacerbation frequency did not change, although 
there seemed to be a reduction in hospitalisation days after NIV 
initiation at home. However, the study was neither designed nor 
powered to find an effect on exacerbations/hospitalisations, and 
therefore, these results should be considered cautiously.
Limitations of the present study are that it was a monocentre 
study in a centre that has a large experience with home initia-
tion of NIV; that home initiation was performed by three expe-
rienced ventilatory nurse specialists and that the telemedicine set 
up used to initiate patients at home included a strict monitoring 
protocol. Therefore, we can only conclude that home initiation 
including this intensive monitoring set up was non- inferior to 
in- hospital initiation. Second, study results cannot be generalised 
to patients who need NIV directly after a COPD exacerbation, as 
all included patients were initiated at least 4 weeks after an exac-
erbation. Nevertheless, the study is representative of the severe 
COPD population; we included patients with severe hyper-
capnia, and although we did not include ‘post- exacerbation’ 
patients, we included both patients who frequently exacerbated 
before, also needing acute NIV, and patients with less frequent 
prior exacerbations not having prior NIV experience. In both 
groups, home initiation was feasible. As the number of patients 
with COPD/obstructive sleep apnea overlap syndrome was very 
small, the study results cannot be formally generalised to these 
patients. Nevertheless, NIV set up did work out very well in 
our overlap patients. The costs calculations depend on the local- 
specific and country- specific situation, such as the actual setting 
of NIV initiation (pulmonary ward, medium care unit and inten-
sive care unit), duration of stay at the ward, health insurance 
fees for outpatient care and the distance that caregivers have to 
travel. However, even if the number of ward days would be 2 
days (one night), the costs would still be higher with hospital 
initiation. Moving the majority of NIV initiations from hospital 
to home will necessitate a change in the staffing model. Most 
importantly, patient preference with home initiation might be an 
at least equally important outcome that results in benefit even 
with equal costs.
To conclude, we showed for the first time that home initia-
tion of NIV with the use of telemedicine in COPD patients with 
CHRF is non- inferior to hospital initiation, safe and associated 
with savings of over 50% of the costs.
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